🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Kerry J. Savage

BC Cancer Agency

ORCID: 0000-0002-5835-9863

Also affiliated with University of British Columbia, Spinal Cord Injury BC, Canadian Centre for Applied Research in Cancer Control

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma

(2023)10.1158/1078-0432.c.6530648.v1
Top 100%
0DataRank
Top 100%0 citations

Alyssa Bouska, Sunandini Sharma, Catalina Amador, Saumyaranjan Mallick, Tyler A. Herek +21 more

Papers

Driven by 13 papers — median percentile 0. Top paper: “Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies”.

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3706
N/A
4.4DataRank · unranked
198 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Blood Advances(2022)10.1182/bloodadvances.2020003971
N/A
1.1DataRank · unranked
40 citations

Steven M. Horwitz, Ranjana H. Advani, Jacob Haaber Christensen, Eva Domingo‐Doménech, Giuseppe Rossi +19 more

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study

The Lancet Haematology(2024)10.1016/s2352-3026(24)00171-6
N/A
0.673DataRank · unranked
20 citations

Jasmine Zain, Kerry J. Savage, Tatyana Feldman, Jonathan E. Brammer, Lu Chen +14 more

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Blood Cancer Journal(2025)10.1038/s41408-025-01329-2
N/A
0.282DataRank · unranked
5 citations

Barbara Pro, Tim Illidge, Steven M. Horwitz, Lorenz Truemper, Swaminathan P. Iyer +22 more

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma

Blood Advances(2025)10.1182/bloodadvances.2024015282
N/A
0.185DataRank · unranked
2 citations

Neha Mehta–Shah, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser +18 more

Data from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma

(2023)10.1158/1078-0432.c.6530648.v1
Top 100%
0DataRank
Top 100%0 citations

Alyssa Bouska, Sunandini Sharma, Catalina Amador, Saumyaranjan Mallick, Tyler A. Herek +21 more

Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda

JCO Oncology Practice(2024)10.1200/op.24.00364
N/A
0DataRank · unranked
6 citations

Kerry J. Savage, Brian K. Link, John P. Leonard, Kara M. Kelly, Gita Thanarajasingam +7 more

TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

Nature Medicine(2020)10.1038/s41591-020-0757-z
N/A
0DataRank · unranked
81 citations

Shannon Healy, Ali Bashashati, Saeed Saberi, Christoffer Hother, Anja Mottok +52 more

126 | THE EARLY‐STAGE CLASSIC HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTICATION INDEX (E‐HIPI): AN INDIVIDUALIZED PREDICTION MODEL UTILIZING OBJECTIVE AND CONTINUOUS VARIABLES

Hematological Oncology(2025)10.1002/hon.70093_126
N/A
0DataRank · unranked
0 citations

Angie May Rodday, Matthew J. Maurer, Jenica Upshaw, Nicholas Counsell, Sabrina Rossetti +19 more

Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0573
N/A
0DataRank · unranked
29 citations

Alyssa Bouska, Sunandini Sharma, Catalina Amador, Saumyaranjan Mallick, Tyler A. Herek +21 more

CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy

Hematological Oncology(2023)10.1002/hon.3164_441
N/A
0DataRank · unranked
1 citations

Diego Villa, Annette E. Hay, Nathalie A. Johnson, Michael Crump, Robert Kridel +10 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017.v1
N/A
0DataRank · unranked
0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017
N/A
0DataRank · unranked
0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more